

# **GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2018**

<https://marketpublishers.com/r/GDEC62ABD58EN.html>

Date: May 2018

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: GDEC62ABD58EN

## **Abstracts**

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2018

### **SUMMARY**

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report GTPase KRas - Pipeline Review, H1 2018, outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 14 and 10 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Metabolic Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Breast Cancer, Lung Cancer, Solid Tumor, Actinic (Solar) Keratosis, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Corneal

Neovascularization, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Macular Degeneration, Melanoma, Osteosarcoma, Prostate Cancer, Small-Cell Lung Cancer and Squamous Cell Carcinoma.

Furthermore, this report also reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects

The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies

Involved in Therapeutics Development

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Codiak BioSciences Inc

Cotinga Pharmaceuticals Inc

InteRNA Technologies BV

Kyowa Hakko Kirin Co Ltd

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Nuevolution AB

PeptiDream Inc

Takeda Pharmaceutical Co Ltd

Tosk Inc

Warp Drive Bio Inc

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles

ARS-853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4785 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
COTI-219 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
HD-001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
INT-1B3 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
KHK-KRAS - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Krasin-100 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
KRpep-2d - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
MM-41 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
mRNA-5671 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

MRTX-849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBT-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KRAS for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KRAS for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit KRAS for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit K Ras for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit K-Ras for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KRAS for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SML-8731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target K-RAS for Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones

Featured News & Press Releases

May 03, 2018: Moderna and Merck Expand mRNA Cancer Vaccines Collaboration

Apr 18, 2018: InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

Nov 13, 2017: Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs

Dec 16, 2016: Ionis Earns \$28 Million from AstraZeneca for a New Drug to Treat Cancer

Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS

Aug 29, 2016: FDA Grants Orphan Drug Designation to SBT-100 for Pancreatic Cancer

Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation

May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement

Jan 03, 2013: Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate For Development, Triggering \$5m Milestone Payment To Dicerna Pharma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Products under Development by Companies, H1 2018 (Contd.2), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by AstraZeneca Plc, H1 2018  
Pipeline by Aurigene Discovery Technologies Ltd, H1 2018  
Pipeline by Boehringer Ingelheim GmbH, H1 2018  
Pipeline by Codiak BioSciences Inc, H1 2018  
Pipeline by Cotinga Pharmaceuticals Inc, H1 2018  
Pipeline by InterRNA Technologies BV, H1 2018  
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018  
Pipeline by Mirati Therapeutics Inc, H1 2018  
Pipeline by Moderna Therapeutics Inc, H1 2018  
Pipeline by Nuevolution AB, H1 2018  
Pipeline by PeptiDream Inc, H1 2018  
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018  
Pipeline by Tosk Inc, H1 2018  
Pipeline by Warp Drive Bio Inc, H1 2018  
Dormant Projects, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Codiak BioSciences Inc

Cotinga Pharmaceuticals Inc

InteRNA Technologies BV

Kyowa Hakko Kirin Co Ltd

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Nuevolution AB

PeptiDream Inc

Takeda Pharmaceutical Co Ltd

Tosk Inc

Warp Drive Bio Inc

## I would like to order

Product name: GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/GDEC62ABD58EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDEC62ABD58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

